IMM0306

2 clinical trials

3 abstracts

2 indications

Indication

Abstract

Preliminary results from a phase I study of IMM0306 in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Org: Affiliated Cancer Hosiptal of Zhengzhou University, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,

Abstract

Phase I safety and preliminary efficacy of IMM0306 in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Org: Lymphatic Comprehensive Internal Medicine Ward, Henan Cancer Hospital, Henan Cancer Hospital, Department of Lymphoma, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,

Clinical trial

A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's Lymphoma

Status: Not yet recruiting, Estimated PCD: 2025-05-01

Clinical trial

Phase I/II Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Status: Recruiting, Estimated PCD: 2025-05-25

Abstract

Preliminary results from a phase I/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, The First Affiliated Hospital of Zhengzhou University,